This 30 year Program brings together 5 Projects and 3 Cores from 2 institutions and 4 labs to explore the physiologic and pathophysiologic roles and signaling of receptors and ligands related to corticotropin releasing factor (CRF), a peptide we chemically identified at the inception of the Program. CRF is the principal neuroregulator of the hypothalamic-pituitary-adrenal (HPA) axis and acts within the brain to integrate endocrine, autonomic and behavioral responses to stressors. Many disorders including anxiety, type 2 diabetes, obesity, drug addiction and depression are associated with perturbations of the HPA axis and changes in production or sensitivity to CRF. We have chemically and biologically characterized multiple components of this system including two receptor genes (CRFR1 and CRFR2), a CRF binding protein and three urocortins (Ucn 1, 2 and 3). CRF and Ucn 1 have high affinity for CRFR1;Ucn 1 has high affinity for both receptor types;Ucn 2 and 3 are highly selective for CRFR2. This program has developed and analyzed mouse mutants that are deficient in the receptors and the three Ucns revealing unexpected roles for these peptides in the CNS, endocrine and cardiovascular systems, skeletal muscle and gastrointestinal tract. We continue our focus on stress and several projects are now emphasizing metabolism, namely control of appetite and regulation of insulin secretion and sensitivity. The 3D structures of the major binding domains of CRF receptors bound to ligands have been solved by NMR and progress has been made towards solubilizing full-length receptors. New potent and selective peptide antagonists of CRFR1 and 2 have been developed and are being used to probe the physiologic significance and the pharmacologic promise of these important signaling systems. Each of the Projects in this Program tests hypotheses relating to CRF and Ucns, and have free access to reagents and models developed within the Program. The Program comprises: Proj 1, W Vale, Project Director (PD): CRF and urocortins and their receptors;Proj 2, J Rivier, PD: Pharmacology of neuroendocrine peptides;Proj 3, S Choe/R Riek, PDs: Structural studies of the interaction between CRF G-protein coupled receptors and their ligands;Proj 4, G Koob/E Zorrilla, PDs: Behavioral significance of neuroendocrine peptides;Proj 5, P Sawchenko, PD: Anatomy of neuroendocrine peptide pathways in the brain;Core A, W Vale, Core Director (CD): Administrative;Core B, K-F Lee/ Vale, CDs: Biology;Core C, J Rivier/W Fischer, CDs: Chemistry. Specifying the contributions of the CRF family of ligands and receptors to the maintenance of homeostasis and to stress-linked allostasis may improve our ability to manage diseases, including mood and metabolic disorders

National Institute of Health (NIH)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Hyde, James F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Salk Institute for Biological Studies
La Jolla
United States
Zip Code
Roustit, Manon M; Vaughan, Joan M; Jamieson, Pauline M et al. (2014) Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle. J Endocrinol 223:143-54
Jappelli, Roberto; Perrin, Marilyn H; Lewis, Kathy A et al. (2014) Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli. PLoS One 9:e84013
van der Meulen, Talitha; Huising, Mark O (2014) Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. Rev Diabet Stud 11:115-32
Zorrilla, Eric P; Logrip, Marian L; Koob, George F (2014) Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol 35:234-44
Rivier, Jean E; Rivier, Catherine L (2014) Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol 35:161-70
Benner, Christopher; van der Meulen, Talitha; Cacéres, Elena et al. (2014) The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15:620
Szabadfi, K; Kiss, P; Reglodi, D et al. (2014) Urocortin 2 treatment is protective in excitotoxic retinal degeneration. Acta Physiol Hung 101:67-76
Koob, George F; Buck, Cara L; Cohen, Ami et al. (2014) Addiction as a stress surfeit disorder. Neuropharmacology 76 Pt B:370-82
Logrip, Marian L; Zorrilla, Eric P (2014) Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. Front Integr Neurosci 8:30
Logrip, Marian L; Vendruscolo, Leandro F; Schlosburg, Joel E et al. (2014) Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology 39:1722-31

Showing the most recent 10 out of 358 publications